Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations — Stella

Recruiting

Back to Non-small Cell Lung Cancer Metastatic trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Key details

Phase

Safety & dosing

Sponsor

Sun Yat-sen University

Enrollment target

~23 participants

Started

July 2024

Primary completion

July 2026

Age range

18 Years and older

Last updated July 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov